OXFORD NANOIMAGING LTD

Their core work

Oxford Nanoimaging is a UK-based technology SME that develops or applies nanoscale imaging technology, contributing specialist analytical capabilities to biomedical research consortia. Their project involvement spans quantitative modelling of biological systems and the rational design of nanoparticles that mimic extracellular vesicles for targeted drug delivery. They bring experimental characterization expertise to multi-partner European research teams working on precision medicine and bioconjugation challenges. With only two H2020 projects on record, both in fundamental research schemes, the full scope of their commercial offering is only partially visible from EU project data alone.

What they specialise in

How they've shifted over time

In their earliest H2020 engagement (PEP-NET, 2018), Oxford Nanoimaging's contribution was framed around quantitative modelling — a computational and theoretical lens on biological systems. By 2021, with MIMIC-KeY, their focus had shifted distinctly toward applied nanomedicine: extracellular vesicles, bioconjugation, targeted drug delivery, and metabolic bone disease as a clinical indication. The direction is clear — from theoretical modelling support toward experimental nanoparticle engineering with therapeutic intent.

Oxford Nanoimaging is moving deeper into applied nanomedicine — specifically nanoparticle-based drug delivery systems — which positions them as a potential technology partner for pharmaceutical and biotech companies working on targeted therapeutics.

How they like to work

Oxford Nanoimaging consistently joins projects as a specialist contributor, never as coordinator, and participates in large multi-partner consortia (21 unique partners across 11 countries from just two projects). This pattern suggests they provide a specific, well-defined technical capability that complements broader research teams rather than driving project strategy. They are a reliable specialist node rather than a consortium hub, making them straightforward to integrate into an existing consortium.

Despite only two projects, Oxford Nanoimaging has reached 21 unique consortium partners across 11 countries, indicating they join well-connected European research networks. Their geographic spread reflects participation in high-prestige FET and MSCA programmes that draw partners from across the EU and beyond.

What sets them apart

Oxford Nanoimaging combines nanoscale imaging technology with a research base in Oxford's dense biomedical ecosystem, giving them proximity to world-class university partners and spinout networks. Their participation in both a computational biology project (PEP-NET) and an applied nanoparticle drug delivery project (MIMIC-KeY) shows they can bridge theory and experiment — a rare combination in SMEs at this scale. As an SME active in the MSCA and FET frameworks, they demonstrate readiness to integrate into academically rigorous, research-heavy consortia alongside major European universities.

Highlights from their portfolio

• MIMIC-KeY
  The only project with direct EC funding (EUR 201,250) and the richest keyword set — extracellular vesicles, drug delivery, cell targeting, metabolic bone disease — making it the clearest window into Oxford Nanoimaging's applied nanomedicine capabilities.
• PEP-NET
  A long-running project (2018-2023) in Predictive Epigenetics that demonstrates Oxford Nanoimaging's capacity to contribute to computation- and theory-driven life science consortia, not just experimental ones.